Skip to main content
. 2017 Dec 27;10(1):7. doi: 10.3390/v10010007

Figure 6.

Figure 6

Vaccine efficacy of recombinant NYVAC-C viruses after single or sequential deletion of VACV-TLR inhibitors A46R, A52R, K7R and B15R. (A) Groups of five BALB/c mice were vaccinated by i.p. inoculation with 107 pfu of the indicated viruses and challenged i.n. one month later with 5 × 106 pfu of wild-type VACV WR. The resulting weight change was monitored daily. Data are expressed as the percentage ± standard error of the mean (SEM) of the mean weight of the same group of animals on day 0. (B) VACV-specific antibody titres and (C) VACV-specific neutralizing titres measured by ELISA and plaque reduction neutralization, respectively, in serum from immunized mice before the i.n. challenge.